Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Enveric Biosciences Inc ENVB

Healthcare
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.


NDAQ:ENVB - Post by User

Enveric Biosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(228)
•••
Post by whytestockson Feb 29, 2024 11:30am
51 Views
Post# 35906623

Enveric Biosciences Pursuing Exclusive Out-Licensing of Thre

Enveric Biosciences Pursuing Exclusive Out-Licensing of Thre
NEWS: $ENVB Enveric Biosciences Pursuing Exclusive Out-Licensing of Three Classes of Compounds2024-02-29 07:32:31 ET DENVER, Colo., Feb 29, 2024 ( 247marketnews.com )- Enveric Biosciences (NASDAQ: ENVB ) stated, this morning, that it signed three non-binding term sheets to pursue the out-licensing of three classes of compounds, with an undisclosed company. Enveric is tra...ENVB - Enveric Biosciences Pursuing Exclusive Out-Licensing of Three Classes of Compounds

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities